Pharmacotherapeutic management of paediatric heart failure and ACE-I use patterns: A European survey

Cristina Castro Díez, Feras Khalil, Holger Schwender, Michiel Dalinghaus, Ida Jovanovic, Nina Makowski, Christoph Male, Milica Bajcetic, Marijke Van Der Meulen, Saskia N. De Wildt, László Ablonczy, A. Szatmári, Ingrid Klingmann, Jennifer Walsh, Stephanie Läer

Research output: Review article

1 Citation (Scopus)

Abstract

Objective To characterise heart failure (HF) maintenance pharmacotherapy for children across Europe and investigate how angiotensin-converting enzyme inhibitors (ACE-I) are used in this setting. Methods A Europe-wide web-based survey was conducted between January and May 2015 among European paediatricians dedicated to cardiology. Results Out of 200-eligible, 100 physicians representing 100 hospitals in 27 European countries participated. All participants reported prescribing ACE-I to treat dilated cardiomyopathy-related HF and 97% in the context of congenital heart defects; 87% for single ventricle physiology. Twenty-six per cent avoid ACE-I in newborns. Captopril was most frequently selected as first-choice for newborns (73%) and infants and toddlers (66%) and enalapril for children (56%) and adolescents (58%). Reported starting and maintenance doses varied widely. Up to 72% of participants follow formal creatinine increase limits for decision-making when up-titrating; however, heterogeneity in the cut-off points selected existed. ACE-I formulations prescribed by 47% of participants are obtained from more than a single source. Regarding symptomatic HF maintenance therapy, 25 different initial drug combinations were reported, although 79% select a regimen that includes ACE-I and diuretic (thiazide and/or loop), 61% ACE-I and aldosterone antagonist; 44% start with beta-blocker, 52% use beta-blockers as an add-on drug. Of the 89 participants that prescribe pharmacotherapy to asymptomatic patients, 40% do not use ACE-I monotherapy or ACE-I-beta-blocker two-drug only combination. Conclusions Despite some reluctance to use them in newborns, ACE-I seem key in paediatric HF treatment strategies. Use in single ventricle patients seems frequent, in apparent contradiction with current paediatric evidence. Disparate dosage criteria and potential formulation-induced variability suggest significant differences may exist in the risk-benefit profile children are exposed to. No uniformity seems to exist in the drug regimens in use. The information collected provides relevant insight into real-life clinical practice and may facilitate research to identify the best therapeutic options for HF children.

Original languageEnglish
Article numbere000365
JournalBMJ Paediatrics Open
Volume3
Issue number1
DOIs
Publication statusPublished - jan. 1 2019

Fingerprint

Angiotensin-Converting Enzyme Inhibitors
Heart Failure
Pediatrics
Newborn Infant
Drug Combinations
Surveys and Questionnaires
Mineralocorticoid Receptor Antagonists
Sodium Potassium Chloride Symporter Inhibitors
Sodium Chloride Symporter Inhibitors
Drug Therapy
Enalapril
Congenital Heart Defects
Captopril
Dilated Cardiomyopathy
Cardiology
Pharmaceutical Preparations
Creatinine
Decision Making
Therapeutics
Maintenance

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Díez, C. C., Khalil, F., Schwender, H., Dalinghaus, M., Jovanovic, I., Makowski, N., ... Läer, S. (2019). Pharmacotherapeutic management of paediatric heart failure and ACE-I use patterns: A European survey. BMJ Paediatrics Open, 3(1), [e000365]. https://doi.org/10.1136/bmjpo-2018-000365

Pharmacotherapeutic management of paediatric heart failure and ACE-I use patterns : A European survey. / Díez, Cristina Castro; Khalil, Feras; Schwender, Holger; Dalinghaus, Michiel; Jovanovic, Ida; Makowski, Nina; Male, Christoph; Bajcetic, Milica; Van Der Meulen, Marijke; De Wildt, Saskia N.; Ablonczy, László; Szatmári, A.; Klingmann, Ingrid; Walsh, Jennifer; Läer, Stephanie.

In: BMJ Paediatrics Open, Vol. 3, No. 1, e000365, 01.01.2019.

Research output: Review article

Díez, CC, Khalil, F, Schwender, H, Dalinghaus, M, Jovanovic, I, Makowski, N, Male, C, Bajcetic, M, Van Der Meulen, M, De Wildt, SN, Ablonczy, L, Szatmári, A, Klingmann, I, Walsh, J & Läer, S 2019, 'Pharmacotherapeutic management of paediatric heart failure and ACE-I use patterns: A European survey', BMJ Paediatrics Open, vol. 3, no. 1, e000365. https://doi.org/10.1136/bmjpo-2018-000365
Díez CC, Khalil F, Schwender H, Dalinghaus M, Jovanovic I, Makowski N et al. Pharmacotherapeutic management of paediatric heart failure and ACE-I use patterns: A European survey. BMJ Paediatrics Open. 2019 jan. 1;3(1). e000365. https://doi.org/10.1136/bmjpo-2018-000365
Díez, Cristina Castro ; Khalil, Feras ; Schwender, Holger ; Dalinghaus, Michiel ; Jovanovic, Ida ; Makowski, Nina ; Male, Christoph ; Bajcetic, Milica ; Van Der Meulen, Marijke ; De Wildt, Saskia N. ; Ablonczy, László ; Szatmári, A. ; Klingmann, Ingrid ; Walsh, Jennifer ; Läer, Stephanie. / Pharmacotherapeutic management of paediatric heart failure and ACE-I use patterns : A European survey. In: BMJ Paediatrics Open. 2019 ; Vol. 3, No. 1.
@article{fb18bf0eca524071a0e3b4ae643ead63,
title = "Pharmacotherapeutic management of paediatric heart failure and ACE-I use patterns: A European survey",
abstract = "Objective To characterise heart failure (HF) maintenance pharmacotherapy for children across Europe and investigate how angiotensin-converting enzyme inhibitors (ACE-I) are used in this setting. Methods A Europe-wide web-based survey was conducted between January and May 2015 among European paediatricians dedicated to cardiology. Results Out of 200-eligible, 100 physicians representing 100 hospitals in 27 European countries participated. All participants reported prescribing ACE-I to treat dilated cardiomyopathy-related HF and 97{\%} in the context of congenital heart defects; 87{\%} for single ventricle physiology. Twenty-six per cent avoid ACE-I in newborns. Captopril was most frequently selected as first-choice for newborns (73{\%}) and infants and toddlers (66{\%}) and enalapril for children (56{\%}) and adolescents (58{\%}). Reported starting and maintenance doses varied widely. Up to 72{\%} of participants follow formal creatinine increase limits for decision-making when up-titrating; however, heterogeneity in the cut-off points selected existed. ACE-I formulations prescribed by 47{\%} of participants are obtained from more than a single source. Regarding symptomatic HF maintenance therapy, 25 different initial drug combinations were reported, although 79{\%} select a regimen that includes ACE-I and diuretic (thiazide and/or loop), 61{\%} ACE-I and aldosterone antagonist; 44{\%} start with beta-blocker, 52{\%} use beta-blockers as an add-on drug. Of the 89 participants that prescribe pharmacotherapy to asymptomatic patients, 40{\%} do not use ACE-I monotherapy or ACE-I-beta-blocker two-drug only combination. Conclusions Despite some reluctance to use them in newborns, ACE-I seem key in paediatric HF treatment strategies. Use in single ventricle patients seems frequent, in apparent contradiction with current paediatric evidence. Disparate dosage criteria and potential formulation-induced variability suggest significant differences may exist in the risk-benefit profile children are exposed to. No uniformity seems to exist in the drug regimens in use. The information collected provides relevant insight into real-life clinical practice and may facilitate research to identify the best therapeutic options for HF children.",
keywords = "cardiology, paediatric practice, pharmacology, therapeutics",
author = "D{\'i}ez, {Cristina Castro} and Feras Khalil and Holger Schwender and Michiel Dalinghaus and Ida Jovanovic and Nina Makowski and Christoph Male and Milica Bajcetic and {Van Der Meulen}, Marijke and {De Wildt}, {Saskia N.} and L{\'a}szl{\'o} Ablonczy and A. Szatm{\'a}ri and Ingrid Klingmann and Jennifer Walsh and Stephanie L{\"a}er",
year = "2019",
month = "1",
day = "1",
doi = "10.1136/bmjpo-2018-000365",
language = "English",
volume = "3",
journal = "BMJ Paediatrics Open",
issn = "2399-9772",
number = "1",

}

TY - JOUR

T1 - Pharmacotherapeutic management of paediatric heart failure and ACE-I use patterns

T2 - A European survey

AU - Díez, Cristina Castro

AU - Khalil, Feras

AU - Schwender, Holger

AU - Dalinghaus, Michiel

AU - Jovanovic, Ida

AU - Makowski, Nina

AU - Male, Christoph

AU - Bajcetic, Milica

AU - Van Der Meulen, Marijke

AU - De Wildt, Saskia N.

AU - Ablonczy, László

AU - Szatmári, A.

AU - Klingmann, Ingrid

AU - Walsh, Jennifer

AU - Läer, Stephanie

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective To characterise heart failure (HF) maintenance pharmacotherapy for children across Europe and investigate how angiotensin-converting enzyme inhibitors (ACE-I) are used in this setting. Methods A Europe-wide web-based survey was conducted between January and May 2015 among European paediatricians dedicated to cardiology. Results Out of 200-eligible, 100 physicians representing 100 hospitals in 27 European countries participated. All participants reported prescribing ACE-I to treat dilated cardiomyopathy-related HF and 97% in the context of congenital heart defects; 87% for single ventricle physiology. Twenty-six per cent avoid ACE-I in newborns. Captopril was most frequently selected as first-choice for newborns (73%) and infants and toddlers (66%) and enalapril for children (56%) and adolescents (58%). Reported starting and maintenance doses varied widely. Up to 72% of participants follow formal creatinine increase limits for decision-making when up-titrating; however, heterogeneity in the cut-off points selected existed. ACE-I formulations prescribed by 47% of participants are obtained from more than a single source. Regarding symptomatic HF maintenance therapy, 25 different initial drug combinations were reported, although 79% select a regimen that includes ACE-I and diuretic (thiazide and/or loop), 61% ACE-I and aldosterone antagonist; 44% start with beta-blocker, 52% use beta-blockers as an add-on drug. Of the 89 participants that prescribe pharmacotherapy to asymptomatic patients, 40% do not use ACE-I monotherapy or ACE-I-beta-blocker two-drug only combination. Conclusions Despite some reluctance to use them in newborns, ACE-I seem key in paediatric HF treatment strategies. Use in single ventricle patients seems frequent, in apparent contradiction with current paediatric evidence. Disparate dosage criteria and potential formulation-induced variability suggest significant differences may exist in the risk-benefit profile children are exposed to. No uniformity seems to exist in the drug regimens in use. The information collected provides relevant insight into real-life clinical practice and may facilitate research to identify the best therapeutic options for HF children.

AB - Objective To characterise heart failure (HF) maintenance pharmacotherapy for children across Europe and investigate how angiotensin-converting enzyme inhibitors (ACE-I) are used in this setting. Methods A Europe-wide web-based survey was conducted between January and May 2015 among European paediatricians dedicated to cardiology. Results Out of 200-eligible, 100 physicians representing 100 hospitals in 27 European countries participated. All participants reported prescribing ACE-I to treat dilated cardiomyopathy-related HF and 97% in the context of congenital heart defects; 87% for single ventricle physiology. Twenty-six per cent avoid ACE-I in newborns. Captopril was most frequently selected as first-choice for newborns (73%) and infants and toddlers (66%) and enalapril for children (56%) and adolescents (58%). Reported starting and maintenance doses varied widely. Up to 72% of participants follow formal creatinine increase limits for decision-making when up-titrating; however, heterogeneity in the cut-off points selected existed. ACE-I formulations prescribed by 47% of participants are obtained from more than a single source. Regarding symptomatic HF maintenance therapy, 25 different initial drug combinations were reported, although 79% select a regimen that includes ACE-I and diuretic (thiazide and/or loop), 61% ACE-I and aldosterone antagonist; 44% start with beta-blocker, 52% use beta-blockers as an add-on drug. Of the 89 participants that prescribe pharmacotherapy to asymptomatic patients, 40% do not use ACE-I monotherapy or ACE-I-beta-blocker two-drug only combination. Conclusions Despite some reluctance to use them in newborns, ACE-I seem key in paediatric HF treatment strategies. Use in single ventricle patients seems frequent, in apparent contradiction with current paediatric evidence. Disparate dosage criteria and potential formulation-induced variability suggest significant differences may exist in the risk-benefit profile children are exposed to. No uniformity seems to exist in the drug regimens in use. The information collected provides relevant insight into real-life clinical practice and may facilitate research to identify the best therapeutic options for HF children.

KW - cardiology

KW - paediatric practice

KW - pharmacology

KW - therapeutics

UR - http://www.scopus.com/inward/record.url?scp=85070210778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070210778&partnerID=8YFLogxK

U2 - 10.1136/bmjpo-2018-000365

DO - 10.1136/bmjpo-2018-000365

M3 - Review article

AN - SCOPUS:85070210778

VL - 3

JO - BMJ Paediatrics Open

JF - BMJ Paediatrics Open

SN - 2399-9772

IS - 1

M1 - e000365

ER -